Ionis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IONS research report →
Range $53 – $115
Price Chart
About the company
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy.
- CEO
- Brett Monia
- IPO
- 1991
- Employees
- 1,480
- HQ
- Carlsbad, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a deep corrective regime, still far below its 200-day moving average and well under its 52-week high. The recent rebound from the low-$27 area shows stabilization, but the longer-term trend remains damaged until price can reclaim the intermediate moving average zone.
Street sentiment stays constructive, with a Buy consensus and a $78.13 average target versus a $29.06 last close. Recent calls were mostly maintained but marked down, with several firms trimming targets into the $53-$80 range while keeping positive ratings.
Ionis has a strong beat pattern, with 8 straight EPS beats and the latest quarter topping estimates by 45.9%. The next setup is about whether revenue growth and pipeline execution can narrow losses, since 2027 EPS is still expected at -$3.01 and 2028 remains volatile.
Insider flow leans modestly positive, led by two discretionary director purchases from Hayden Michael R. totaling 20,000 shares. Most other activity was automatic equity awards, vesting, or tax-related sales, so the signal is constructive but not broad-based.
Growth is solid but profitability remains weak, with revenue up 54.9% year over year while net margin is -56.9% and operating margin is -58.8%. The balance sheet is still workable, with $2.68 billion in cash against $2.61 billion of debt and a small net cash position.
Ionis wins on pipeline breadth and commercial-stage RNA franchises, but it still trails peers on earnings quality and margin structure. At a negative P/E and a sub-sector multiple profile, the setup reflects a development-heavy biotech rather than a mature cash compounder.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.43B
- P/E
- -8.20
- Fwd P/E
- 31.12
- PEG
- 0.10
- P/S
- 4.72
- P/B
- 11.49
- EV/EBITDA
- -13.49
- Div Yield
- 0.00%
- Gross Margin
- 98.22%
- Op Margin
- -58.91%
- Net Margin
- -56.90%
- ROE
- -120.44%
- ROIC
- -21.61%
Latest fiscal year · YoY change
- Revenue
- $944.00M+33.9%
- Gross Profit
- $928.00M+33.7%
- Op Income
- $-382,000,000
- Net Income
- $-381,000,000+16.1%
- EPS
- $-2.38+21.7%
- OCF Growth
- +46.4%
- FCF Growth
- +41.4%
- 52W High
- $86.74
- 52W Low
- $26.53
- 50D MA
- $41.32
- 200D MA
- $63.37
- Beta
- 0.40
- RSI (14)
- 24
- Avg Volume
- 3.91M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ionis reported strong overall revenue growth and progress across its commercial portfolio and pipeline, but lowered full-year TRYNGOLZA revenue guidance due to a slower-than-expected launch ramp.· November 9, 2026
- Q3 revenue was $243 million, up 55% year over year excluding last year’s $280 million one-time sapablursen payment; year-to-date revenue was $757 million, up 64%.
- Commercial revenue rose to $136 million in Q3, driven mainly by DAWNZERA and early TRYNGOLZA sales; partner revenue was $107 million in Q3.
- TRYNGOLZA Q3 product sales were $9 million and full-year 2026 guidance was cut to about $50 million from a prior expectation, reflecting a more gradual launch.
- DAWNZERA remains a key growth driver, with Q3 product sales of $37 million and management reaffirmed full-year net sales guidance of $110 million to $120 million.
- Ionis ended Q3 with $1.9 billion in cash and investments and kept 2026 total revenue guidance at $875 million to $900 million, with non-GAAP operating loss guidance of $425 million to $475 million.
Ionis reported third-quarter 2026 revenue of $243 million and year-to-date revenue of $757 million, representing year-over-year growth of 55% and 64%, excluding the $280 million one-time sapablursen payment received last year. Commercial revenue was $136 million in Q3 and $363 million year-to-date, up 18% and 23% year over year, while partner portfolio revenue was $107 million in Q3 and $394 million year-to-date. DAWNZERA generated $37 million in Q3 product sales and $79 million year-to-date, increasing about 40% in the quarter. TRYNGOLZA generated $9 million in Q3 product sales and $41 million year-to-date; management lowered full-year 2026 TRYNGOLZA revenue guidance to approximately $50 million. The company ended Q3 with $1.9 billion in cash and investments and reaffirmed 2026 total revenue guidance of $875 million to $900 million, DAWNZERA net sales guidance of $110 million to $120 million, non-GAAP operating loss guidance of $425 million to $475 million, and year-end cash greater than $1.6 billion.
Brett Monia said Ionis is evolving into a commercial-stage biotech with multiple growth drivers across TRYNGOLZA, DAWNZERA and ZANVASTRO, while its pipeline continues to produce approvals and positive data. His tone was confident but pragmatic: he acknowledged two recent Phase III disappointments and the slower TRYNGOLZA launch, but emphasized that the company remains on track for full-year financial guidance and still sees multibillion-dollar peak potential for TRYNGOLZA. He repeatedly framed 2027 as an important year for TRYNGOLZA and for the company’s broader launch and pipeline progression.
Beth Hougen highlighted Q3 revenue of $243 million, year-to-date revenue of $757 million, and commercial revenue of $136 million in the quarter, with DAWNZERA and TRYNGOLZA as key contributors. She said operating expenses rose as expected due to commercialization investments and continued pipeline spend, but Ionis still expects full-year total revenue of $875 million to $900 million, non-GAAP operating loss of $425 million to $475 million, and year-end cash above $1.6 billion. She also said the company is still committed to sustained positive cash flow, but timing is shifting later, with breakeven now expected in 2029 rather than 2028 because of the slower TRYNGOLZA ramp and the recent Phase III setbacks.
Analysts focused heavily on TRYNGOLZA, asking about the slowdown versus earlier launch comments, the split between demand and operational friction, payer coverage, Quick Start, specialty-pharmacy strategy, and whether the launch implications change 2027 expectations. Management said the core issue is not lack of physician enthusiasm but the work of building a brand-new market: prescriber education, converting first prescriptions into repeat prescribing, and improving reimbursement/access. They said approximately 1,500 prescribers had written TRYNGOLZA by the end of September, 24% had written more than one prescription, and 33% of commercial plans had added the sHTG indication to formularies; they also said they are seeing increasing repeat prescribing and improving coverage, but that these dynamics take time to translate into paid starts.
The call showed real commercial momentum in DAWNZERA, with sequential growth each quarter and repeat prescribing expanding, while ZANVASTRO has already reached first commercial patients after approval. Management also said TRYNGOLZA has strong physician enthusiasm, growing prescriber breadth, and improving payer coverage, and they continue to believe it can become a multibillion-dollar product. Beyond the commercial portfolio, Ionis pointed to multiple pipeline and partnered-program wins, including HIBSAGO approval and positive Phase III data for Sefaxersen and ulefnersen.
The biggest risk on this call is that TRYNGOLZA is ramping more slowly than expected, prompting a cut to full-year sales guidance and pushing breakeven later to 2029. Management said the launch is being slowed by the need to build a new treatment paradigm, navigate medical exceptions and access, and educate physicians and patients, which means revenue may stay uneven near term. The company also acknowledged two recent Phase III disappointments, which tempers enthusiasm despite the positive regulatory and pipeline news.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 166.54M
- Float Shares
- 165.18M
of shares held by institutions
559 13F filers
Buy/sell ratio 2.45. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IONS, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 24.74M | ▲ 108.15K |
| Capital World Investors | 21.79M | ▲ 118.05K |
| Vanguard Group Inc | 16.44M | ▼ 41.27K |
| Blackrock, Inc. | 13.19M | ▲ 2.49M |
| Vanguard Portfolio Management LLC | 7.72M | ▼ 140.06K |
| Wellington Management Group Llp | 7.65M | ▲ 1.26M |
| Vanguard Capital Management LLC | 7.22M | ▲ 7.03K |
| Two Sigma Investments, LP | 6.25M | ▲ 394.71K |
| Royal Bank Of Canada | 6.18M | ▲ 2.38M |
| State Street Corp | 5.71M | ▲ 1.38M |
| T. Rowe Price Investment Management, Inc. | 3.96M | ▼ 2.20M |
| Geode Capital Management, LLC | 3.28M | ▼ 306.45K |
Held by 517 ETFs
Biggest fund positions in IONS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Hayden Michael R | buy | 5,000 |
| Oct 15, 26 | Devers Shannon L. | other | 2,820 |
| Oct 15, 26 | Devers Shannon L. | other | 2,820 |
| Oct 16, 26 | Devers Shannon L. | sell | 1,357 |
| Oct 15, 26 | Swayze Eric | other | 125 |
| Oct 15, 26 | Swayze Eric | other | 125 |
| Oct 16, 26 | Swayze Eric | sell | 53 |
| Aug 31, 26 | BENNETT C FRANK | other | 110 |
| Aug 31, 26 | O'NEIL PATRICK R. | other | 63 |
| Aug 31, 26 | Monia Brett P | other | 98 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IONS coverage
Recent articles, reports, and earnings notes.

Ionis Pharmaceuticals (IONS): Commercial Launches Drive the Thesis
Ionis is transitioning from a partnership-heavy biotech into a commercial company, led by TRYNGOLZA and DAWNZERA launches. The stock looks promising, but losses, negative free cash flow, and a rich valuation keep the rating at Hold.

City Therapeutics IPO: What Investors Need to Know
City Therapeutics Inc. (NASDAQ: CTY) is expected to list on October 16, 2026, on the NASDAQ, with the IPO priced at $18.00 per share for 11,111,111 shares. The company has not disclosed a public price range in the calendar data, but the deal was upsized, which points to solid demand. Bull case: early clinical RNAi data and a deep platform story. Bear case: it is still pre-commercial, loss-making, and years away from proving the pipeline.

ADARx Pharmaceuticals IPO Preview: RNA Pipeline Meets Cash Burn
ADARx Pharmaceuticals is expected to list on NASDAQ on 2026-09-25, with shares priced in a $15.00 to $17.00 range. The company is offering 21,875,000 shares and has disclosed an implied market cap of $427,656,250. The setup favors investors who want late-stage RNA exposure, but the key watch item is whether the market gives credit to the pipeline before more clinical data arrives.
Want a deeper read on IONS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch
marketbeat.com · Nov 20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
prnewswire.com · Nov 19
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
zacks.com · Nov 18
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease
businesswire.com · Nov 17
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
gurufocus.com · Nov 17
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
businesswire.com · Nov 17
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
marketbeat.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice